First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
Falchi, L. Offner, F. Belada, D. Brody, J. Karimi, Y. Cordoba, R. Snauwaert, S. Abbas, A. Wang, L. W.
Falchi, L.
Offner, F.
Belada, D.
Brody, J.
Karimi, Y.
Cordoba, R.
Snauwaert, S.
Abbas, A.
Wang, L. W.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Falchi L, Offner F, Belada D, Brody J, Linton KM, Karimi Y, et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301984.